Investigating how protein kinases affect antifungal drug resistance in Candida glabrata
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
This study is looking at how certain proteins in the fungus Candida glabrata help it resist antifungal medicines, and by creating different versions of this fungus, the researchers hope to find new ways to make these treatments work better for people with infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10986728 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of protein kinases in the antifungal drug resistance of the fungus Candida glabrata. The team will create a library of mutant strains of this fungus that lack specific protein kinases and will systematically test these mutants to see how they respond to various antifungal treatments. By analyzing the regulation networks and functions of these kinases, the researchers aim to uncover new targets for antifungal drug development, potentially leading to more effective treatments for infections caused by this pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by Candida glabrata, particularly those who have experienced treatment failures with existing antifungal medications.
Not a fit: Patients with infections caused by other types of fungi or those who do not have drug-resistant strains of Candida glabrata may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal therapies that are more effective against drug-resistant strains of Candida glabrata.
How similar studies have performed: Previous research has shown success in targeting protein kinases to combat drug resistance in other pathogens, indicating that this approach may be promising.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Vu, Bao Gia — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Vu, Bao Gia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.